The DOI matches its Crossref record; 228 of the 228 references it cites were found in a registry or an index.
Antiestrogens and Selective Estrogen Receptor Modulators as Multifunctional Medicines. 2. Clinical Considerations and New Agents
Open accessAbstract
ADVERTISEMENT RETURN TO ISSUEPerspectiveNEXTAntiestrogens and Selective Estrogen Receptor Modulators as Multifunctional Medicines. 2. Clinical Considerations and New AgentsV. Craig JordanView Author Information Robert H. Lurie Comprehensive Cancer Center, The Feinberg School of Medicine of Northwestern University, 303 East Chicago Avenue, MS N505, Chicago, Illinois 60611 Cite this: J. Med. Chem. 2003, 46, 7, 1081–1111Publication Date (Web):February 27, 2003Publication History Received9 October 2002Published online27 February 2003Published inissue 1 March 2003https://pubs.acs.org/doi/10.1021/jm020450xhttps://doi.org/10.1021/jm020450xreview-articleACS PublicationsCopyright © 2003 American Chemical SocietyRequest reuse permissionsArticle Views2158Altmetric-Citations335LEARN ABOUT THESE METRICSArticle Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.Citations are the number of other articles citing this article, calculated by Crossref and updated daily. Find more information about Crossref citation counts.The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on the Altmetric Attention Score and how the score is calculated. Share Add toView InAdd Full Text with ReferenceAdd Description ExportRISCitationCitation and abstractCitation and referencesMore Options Share onFacebookTwitterWechatLinked InRedditEmail Other access optionsGet e-Alertsclose SUBJECTS:Cancer,Cancer therapy,Cells,Receptors,Rodent models Get e-Alerts
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–228 of 228
Herrington, D. M., Pusser, B. E., Riley, W. A., Thuren, T. Y., Brosnihan, K. B., Brinton, E. A., & MacLean, D. B. (2000) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.20.6.1606 · Cited by 54
Short- and long-term estrogen deprivation of T47D human breast cancer cells in culture
Murphy, C. S., Meisner, L. F., Wu, S. Q., & Jordan, V. C. (1989) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(89)90348-9 · Cited by 53
Self-citationSchafer, J. M., Lee, E. S., Dardes, R. C., Bentrem, D. J., O'Regan, R. M., Reyes, A. D. L., & Jordan, V. C. (2001) · PubMed · Cited by 52
Self-citationFournier, B., Gutzwiller, S., Dittmar, T., Matthias, G., Steenbergh, P. H., & Matthias, P. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m105418200 · Cited by 51
A New Interpretation of Antiestrogen Actiona
Hedden, A., Müller, V., & Jensen, E. V. (1995) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1995.tb31373.x · Cited by 51
Weatherman, R. V., & Scanlan, T. S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m005414200 · Cited by 51
The Two Faces of Janus: Sex Steroids as Mediators of Both Cell Proliferation and Cell Death
Soto, A. M., & Sonnenschein, C. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.22.1673 · Cited by 51
Antiproliferative effects of idoxifene in a placebo-controlled trial in primary human breast cancer.
Dowsett, M., Dixon, J. M., Horgan, K. J., Salter, J., Hills, M., & Harvey, E. (2000) · PubMed · Cited by 50
Fugère, P., Scheele, W. H., Shah, A. S., Strack, T. R., Glant, M. D., & JOLLY, E. E. (2000) · American Journal of Obstetrics and Gynecology · doi:10.1067/mob.2000.104768 · Cited by 50
Pharmacokinetics of Droloxifene and Its Metabolites in Breast Cancer Patients
Grill, H. ‐., & Pollow, K. (1991) · American Journal of Clinical Oncology · doi:10.1097/00000421-199112002-00006 · Cited by 47
Sourla, A., Luo, S., Labrie, C., Bélanger, A., & Labrie, F. (1997) · Endocrinology · doi:10.1210/endo.138.12.5560 · Cited by 46
Couillard, S., Gutman, M., Labrie, C., Bélanger, A., Candas, B., & Labrie, F. (1998) · PubMed · Cited by 46
Chan, C. M. W., Lykkesfeldt, A. E., Parker, M. G., et al. (1999) · PubMed · Cited by 45
van den Berg, H., Lynch, M., Martin, J., Nelson, J., Dickson, G., & Crockard, A. (1989) · British Journal of Cancer · doi:10.1038/bjc.1989.107 · Cited by 44
Ke, H. Z., Chen, H. K., Qi, H., Pirie, C. M., Simmons, H. A., Ma, Y., Jee, W. S. S., & Thompson, D. D. (1995) · Bone · doi:10.1016/8756-3282(95)00346-2 · Cited by 42
Luo, S., Labrie, C., Bélanger, A., Candas, B., & Labrie, F. (1998) · Breast Cancer Research and Treatment · doi:10.1023/a:1005928814521 · Cited by 37
Martel, C., Labrie, C., Bélanger, A., Gauthier, S., Mérand, Y., Li, X., Provencher, L., Candas, B., & Labrie, F. (1998) · Endocrinology · doi:10.1210/endo.139.5.5968 · Cited by 35
Luo, S., Labrie, C., Bélanger, A., & Labrie, F. (1997) · Endocrinology · doi:10.1210/endo.138.8.5345 · Cited by 34
RU 58668: Further in vitro and in vivo pharmacological data related to its antitumoral activity
Velde, P. V. D., Nique, F., Planchon, P., Prevost, G. P., Brémaud, J., HAMEAU, M., Magnien, V., Philibert, D., & Teutsch, G. (1996) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(96)00140-9 · Cited by 33
Luo, S., Sourla, A., Labrie, C., Gauthier, S., Mérand, Y., Bélanger, A., & Labrie, F. (1998) · Endocrinology · doi:10.1210/endo.139.5.5994 · Cited by 33
Webb, P., Nguyen, P., Valentine, C. D., Weatherman, R., Scanlan, T., & Kushner, P. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m007435200 · Cited by 28
Hu, J., & Mokbel, K. (2001) · European Journal of Surgical Oncology · doi:10.1053/ejso.2000.1078 · Cited by 27
Luo, S., Stojanovic, M. M., Labrie, C., & Labrie, F. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19971114)73:4<580::aid-ijc20>3.0.co;2-c · Cited by 27
Structural components necessary for the antiestrogenic activity of tamoxifen
Murphy, C. S., & Jordan, V. C. (1989) · Journal of Steroid Biochemistry · doi:10.1016/0022-4731(89)90117-9 · Cited by 22
Self-citationLi, S., L�vesque, C., Geng, C.-S., Yan, X., & Labrie, F. (1995) · Breast Cancer Research and Treatment · doi:10.1007/bf00665787 · Cited by 19
Lack of evidence for tamoxifen- and toremifene-DNA adducts in lymphocytes of treated patients
Bartsch, H., Phillips, D. H., Nair, J., et al. (2000) · Carcinogenesis · doi:10.1093/carcin/21.4.845 · Cited by 19
Long term survivors of childhood brain cancer have an increased risk for cardiovascular disease
(2000) · Pure Amsterdam UMC · doi:10.1002/(sici)1097-0142(20000501)88:9
Cited by
Wang, J., Sánchez-Roselló, M., Aceña, J. L., del Pozo, C., Sorochinsky, A. E., Fustero, S., Soloshonok, V. A., & Liu, H. (2014) · Chemical Reviews · doi:10.1021/cr4002879 · Cited by 4,847
Modern Synthetic Methods for Fluorine‐Substituted Target Molecules
Shimizu, M., & Hiyama, T. (2005) · Angewandte Chemie International Edition · doi:10.1002/anie.200460441 · Cited by 830
Estrogen receptors alpha (ERα) and beta (ERβ): Subtype-selective ligands and clinical potential
Paterni, I., Granchi, C., Katzenellenbogen, J. A., & Minutolo, F. (2014) · Steroids · doi:10.1016/j.steroids.2014.06.012 · Cited by 721
Structural Overview of the Nuclear Receptor Superfamily: Insights into Physiology and Therapeutics
Huang, P., Chandra, V., & Rastinejad, F. (2010) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021909-135917 · Cited by 533
Resveratrol as an anticancer nutrient: molecular basis, open questions and promises
Signorelli, P., & Ghidoni, R. (2005) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2005.01.017 · Cited by 489
Metadata
- Authors
- Jordan, V. C.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2003-02-27
- Volume
- 46
- Issue
- 7
- Pages
- 1081-1111
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2148979187
- Cited by
- 396
- References
- 228
- FWCI
- 19.09
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
